INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - ATNM

1. Class action lawsuit filed against Actinium Pharmaceuticals for alleged securities fraud. 2. Lawsuit pertains to officers' potentially unlawful business practices. 3. Investors can apply as Lead Plaintiff until May 26, 2025. 4. Past regulatory setback led to a 60% stock price drop on August 5, 2024. 5. Pomerantz LLP recognized for fighting securities fraud and corporate misconduct.

Legal

75

4m saved

Insight

Article

FAQ

Why Very Bearish?

The class action lawsuit indicates serious legal issues which could severely impact investor sentiment and stock value. Historical precedents show class actions often correlate with stock declines, as seen with Actinium's previous BLA setback.

How important is it?

Given the severity of the allegations of securities fraud and the potential for significant financial ramifications, this article is highly relevant to stock performance.

Why Short Term?

The immediate concern surrounding the lawsuit and associated market reactions will likely affect stock performance quickly, given the investor anxiety and upcoming dates regarding the class action.

Related Companies

ALNY BMY VRTX

Class Action Lawsuit Filed Against Actinium Pharmaceuticals, Inc.

NEW YORK, May 6, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company") (NYSE: ATNM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

The class action concerns whether Actinium and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

You have until May 26, 2025 to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Actinium securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.

Click here for information about joining the class action

On August 5, 2024, Actinium issued a press release "announc[ing] a regulatory update on the Company's planned Biologics License Application ('BLA') filing for Iomab-B in patients with active relapsed or refractory acute myeloid leukemia ('r/r AML')." The press release stated, in relevant part, that the U.S. Food and Drug Administration had "determined that the Phase 3 SIERRA trial is not adequate to support a BLA filing for Iomab-B despite its statistically significant primary endpoint[.]"

On this news, Actinium's stock price fell $3.69 per share, or nearly 60%, to close at $2.48 per share on August 5, 2024.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT: Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

SOURCE Pomerantz LLP